Expert Interview
A 2nd look at Anteris’ DurAVR® Transcatheter Heart Valve (THV) for the treatment of aortic stenosis ahead of pivotal Phase 3 PARADIGM trial
Ticker(s): AVR, EW, MDT, ABTInstitution: University of Michigan
- Interventional Cardiologist and Clinical Scientist at the University of Michigan
- Manages 100 patients per month for inheritied heart diseases
- Research focuses on exploring the molecular and cellular response to myocardial stress and its role in cardiac remodeling
Roughly how many patients with severe aortic stenosis do you evaluate or treat for TAVR each year?
Added By: sara_adminHow do current commercial TAVR devices perform in small annuli patients in your practice, and what unmet needs remain that a valve like DurAVR® may address?
Added By: sara_adminWhat are your impressions of the PARADIGM pivotal trial design, and what data would you need to see to adopt a new biomimetic TAVR platform into routine practice?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
